RxDoctor Payments Data

Leslie Mohlman, MD

Internal Medicine · Bristol, RINPI 1265433262

Payments from drug & device makers

$538in general payments, 2019–2025

Across 25 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organon$165
  • GSK$46
  • Novo Nordisk$41
  • Pfizer$37
  • Sanofi-aventis U.S. LLC$33
  • Amarin Pharma, Inc.$30
  • plus $187 from 9 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$538 in reported general payments places this provider in the 75th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$40,357
Medicare patients
378
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$31,538
MounjaroTirzepatide18$28,007
XareltoRivaroxaban14$12,629
Incruse ElliptaUmeclidinium Bromide12$12,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,886
TradjentaLinagliptin13$11,206
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,218
Arnuity ElliptaFluticasone Furoate16$6,145
Breo ElliptaFluticasone/Vilanterol14$5,943
Spiriva RespimatTiotropium Bromide11$5,799
LivaloPitavastatin Calcium14$4,639
Atorvastatin Calcium313$3,988
Solifenacin Succinate14$1,827
Potassium Chloride29$1,536
Levothyroxine Sodium102$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKIncruse Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta$46$44,46366 claims
PfizerEliquis$37$31,53834 claims
Lilly USA, LLCMounjaro$30$28,00718 claims
Johnson & JohnsonXarelto$16$12,62914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Bristol

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →